Global Information
회사소개 | 문의

세계의 제대혈 은행 산업

Complete 2017-18 Global Cord Blood Banking Industry Report

리서치사 BIOINFORMANT WORLDWIDE, LLC
발행일 2017년 09월 상품 코드 247398
페이지 정보 영문 265 Pages
가격
US $ 3,795 ₩ 4,228,300 PDF by E-mail (Single User License)
US $ 3,995 ₩ 4,451,200 PDF by E-mail (Single User License) & Hard Copy
US $ 4,495 ₩ 5,008,300 PDF by E-mail (Site License)
US $ 4,995 ₩ 5,565,400 PDF by E-mail (Global License)


세계의 제대혈 은행 산업 Complete 2017-18 Global Cord Blood Banking Industry Report
발행일: 2017년 09월 페이지 정보 : 영문 265 Pages

한글목차

세계의 제대혈 시장은 과거 수년간 성숙화되었으며, 새로운 시장 기회를 창출하고 있지만 심각한 위협을 야기시키기도 합니다.

세계의 제대혈 은행(Cord Blood Banking) 산업 현황과 전망에 대해 조사했으며, 제대혈 은행의 발전 경위, 현재 및 향후 제대혈 이식을 통해 치료 가능한 질환, 제대혈 은행의 종류, 관련 제도·규제·인가·요건, 제대혈 은행의 매출 성장 예측, 산업에 변화를 가져오는 주요 사건, 지역별 동향, 주요 은행과 업계의 영향력자(Influencer) 분석 등의 정보를 전해드립니다.

제1장 요약

제2장 제대혈 기술과 의학적 특징 개요

  • 제대혈 및 제대조직 : 서론
  • 정의와 명명법
  • 제대혈의 기술적 이점
  • 줄기세포 이식을 필요로 할 가능성
    • 유아기의 확률
    • 성인기의 확률
  • 제대혈·골수·말초혈 줄기세포 이식 비교
  • 제대혈 이식으로 치료할 수 있는 증상

제3장 제대혈 시장 개요

  • 시장 변화
  • 제대혈 은행의 구조
  • 인증 기준 및 요건
    • 인증 유형
    • 혈액은행협회(AABB)의 인증

제4장 제대조직 시장 개요

  • 제대조직 보관 역사
  • 제대혈과 제대조직 보관 비교
  • 간충직 줄기세포에서 생성된 제대조직을 연구하는 임상시험
  • 제대조직의 미국 시장 침투
  • 제대조직 보관 요금(전세계 분석)

제5장 제대혈 산업의 주요 사건 타임라인

제6장 제대혈 시장의 주요 처리 기술

제7장 전략적 공동 개발 : 제대혈 시장의 주요 제휴

  • Cord Blood Registry와 Women's Health Alliance
  • ViaCord와 Destination Maternity(세계 최대 규모의 임부복 소매업체)
  • Precious Cells Miracle과 Croydon Health Services NHS Trust
  • CarePilot과 "Cord for Life"(Lifeforce Cryobank의 제대혈 보관 프로그램)
  • Cesca Therapeutics와 UpState Cord Blood Bank

제8장 제대혈 산업 동향 : 줄기세포 바이오뱅크 내의 다양화

  • 개요
  • 치과 줄기세포 보관
  • 지방 줄기세포 보관
  • 기타 줄기세포 바이오뱅크 종류 : 태반 조직, 월경혈 유줄기세포, 말초혈 줄기세포, 골수 줄기세포, 골수 줄기세포 등

제9장 제대혈 시장의 리더 : 비교 분석

  • 최대의 척수 혈액 뱅크(보관 개수 기준)
    • 미국의 주요 3개 제대혈 은행 비교 분석
    • 세계의 주요 3개 제대혈 은행 비교 분석
  • 가장 빠르게 성장하는 제대혈 은행(매출 기준)
  • 미국 분석
  • 세계 분석

제10장 SWOT 분석

제11장 각종 동향 : 비율 분석

  • 과학 논문 비율 분석
  • 지원금 지급 분석
  • 특허 분석
  • 임상시험 비율 분석
    • 정량적 분석(연도별)
    • 지역 분석
  • 제대혈 보관 시장 보급률

제12장 제대혈 마케팅 분석 : 검색 용어 "제대혈", "제대세포"

제13장 제대혈 산업 주요 벤치마크

  • 제대혈 은행에 대한 의료 부문의 견해
  • 부모의 인식률
  • 세계의 보관율(연도별)
  • 이식 데이터
  • 품질 보증 비교

제14장 시장 규모 분석

  • 정의
  • 조사 방법
  • 시장 규모 추정

제15장 세계 제대혈 시장의 권력자 분석

  • 인물 : 제대혈 업계의 TOP 5 영향력자(Influencer)
  • 세계의 TOP 10 제대혈 은행
  • 이벤트 : 세계의 제대혈 관련 컨퍼런스 및 이벤트
  • 제대혈 시장에 영향을 미치는 투자가와 인수

제16장 제대혈 시장에 영향을 미치는 투자가와 인수

  • 투자가
  • 인수

제17장 제대혈 산업 분석 : 지역에 따른 상황 변화

  • 중국
  • 프랑스 및 이탈리아
  • 대만
  • 에콰도르
  • 남아프리카공화국
  • 브라질

제18장 제대혈 은행 조사 : 600명 이상의 부모 또는 출산 예정인 부모

제19장 결론 : 요약

부록

LSH 15.08.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문목차

Over the past five years, the global cord blood banking industry has substantially matured and consolidated. This has created both serious threats and novel opportunities for the industry. Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation.

Marketing pressures are also impacting the industry, with the term "cord blood" being one of the 20 most expensive search terms on Google. Winning online traffic through Google AdWords for the search phrase "Cord Blood" now costs $45.87 in the U.S. When all locations are allowed, the cost for acquiring online traffic through Google AdWords for the phrase "Cord Blood" is $32.91.

Digital competition for cord blood has also been growing increasingly competitive, with cord blood banks competing for online viewership of ads, website content, and ultimately, clients. Most cord blood banks are using Google Adwords to display advertisements within Google Search as a method of acquiring online visitors. Industry leaders are also publishing enormous quantities of industry-relevant content to dominate in organic (non-paid) online search.

However, there are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading countries worldwide, including the U.S., Japan, and South Korea. Cord blood banks are diversifying into new types of stem cell storage, including cord tissue storage, placental stem cells, amniotic stem cells, menstrual stem cells, adipose tissue, and more.

Holding companies are emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has been acquiring cord blood banks throughout Latin America and Sanpower Group has been collecting them within Asia. Additionally, growing investment is flowing into cord blood stem cell expansion technologies. Key strategies being explored for this purpose include nicotinamide-mediated (NAM) expansion, Notch ligand, SR-1, UM171, PGE2, and enforced fucosylation. Major market players competing in this space include Gamida Cell Ltd, Nohla Therapeutics, Novartis, Fate Therapeutics, and others.

Finally, growing numbers of investors are entering the cord blood banking marketplace, led by groups such as:

  • ABS Capital Partners & HLM Management
  • KKR & Company
  • Bay City Capital
  • GTCR, LLC
  • Excalibur

While market factors can vary by geography, it is crucial to have a global understanding of the market. Research advances, clinical trial findings, and technology advances do not know international boundaries. The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.

Today, cord blood banks now exist in every developed country, as well as within most developing nations. With approximately 450 companies marketing cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share. While the U.S. cord blood banking industry is the most mature cord blood banking market in the world, Asia is extremely close behind and growing more quickly than the U.S. market.

In 2016, Sanpower Group and its subsidiary Nanjing Cenbest announced the acquisition of China Cord Blood Corporation (NYSE:CO) and Shandong Cord Blood Bank, positioning it to hold four licenses out of the only seven issued provincial-level cord blood bank licenses in China. According to the company, Sanpower Group has "reserved 800,000 cord blood samples at home, and the associated reserves nearly amount to 1,100,000 when counting in the Cordlife reserves across various Southeast Asian countries and regions." This positions Sanpower Group and its subsidiary Nanjing Cenbest as the world's largest cord blood banking operator not only in China and Southeast Asia, but in the world.

Currently, the largest cord blood bank in the United States, Cord Blood Registry, reports to have nearly 700,000 cord blood and tissue units in storage, positioning it substantially behind Sanpower Group. With CBR controlling more than 50% of the market share in the U.S. and Sanpower Group controlling more than 50% of the market share in China, these two entities are the largest cord blood operators in the world.

Other regions have witnessed major events as well. In 2008, a Taiwanese company, HealthBanks Biotech Company Ltd. became the first company to offer cord tissue storage. It was not until July 2010 that the first private U.S. cord blood bank began offering the service (Cord Blood Registry). Since then, the trend of cord tissue storage has had a major impact on the cord blood banking industry, with a large percentage of cord blood banks offering the service worldwide.

In China, the government shocked the industry by announcing that only one cord blood bank would be allowed to operate within each province, and official government support, authorization, and permits would be required.

In Italy and France, it is illegal to privately store one's cord blood, which has fully eliminated the potential for a private market to exist within the region.

In Ecuador, the government is now creating the first public cord blood bank and has instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This created a crisis for the private banks, and there are now only two remaining in Ecuador.

Clearly, it is vital to understand market dynamics and risks, as well as the emerging opportunities, within different regions of the world.

This 265 page reports includes:

  • Market size determinations by market segment
  • Trend data for umbilical cord blood grants, patents, and scientific publications
  • Clinical trial analysis, including comparison of cord blood vs. cord tissue
  • Rates of worldwide cord blood storage (units per year)
  • Current and future conditions treatable with cord blood
  • Probability of requiring a stem cell transplant by age
  • Regulatory pathways affecting cord blood banking in major healthcare markets
  • Digital marketing assessment and comparison of industry leaders
  • Competitive environment analysis, including identification of market leaders
  • Medical opinions of cord blood banking
  • Crucial trends and unmet market needs
  • And more

Table of Contents

I. Abstract

II. Timeline of Key Events

III. Technical & Medical Characteristics of Cord Blood

  • A. Introduction to Cord Blood and Cord Tissue
  • B. Definitions and Nomenclature
  • C. Technical Advantages of Cord Blood
  • D. Likelihood of Needing a Stem Cell Transplant
  • E. Comparison of Cord Blood, Bone Marrow, & Peripheral Blood Stem Cell Transplant
  • F. Conditions Treatable with Cord Blood Transplant

IV. Cord Blood Market Overview

  • A. Stem Cell Storage Service Offerings
  • B. Public vs. Private Cord Blood Storage

V. Cord Tissue Market Overview

  • A. History of Cord Tissue Storage
  • B. Comparison of Cord Blood & Cord Tissue Storage
  • C. Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
  • D. Sources of Mesenchymal Stem Cells
  • E. Market Penetration of Cord Tissue Storage within the U.S.
  • F. Market Penetration of Cord Tissue Storage Worldwide
  • G. Pricing of Cord Tissue Storage (Global Analysis)

VI. Benefits of Mesenchymal Stem Cells

  • A. Key Dates in the Discovery of MSCs
  • B. Physical Assessment of MSCs
  • C. Benefits of MSCs Relative to Other Stem Cells
    • 1. Well-Characterized
    • 2. Non-Controversial
    • 3. Diverse Differentiation Potential
    • 4. Ease of Growth in Culture
    • 5. Flexible Propagation
    • 6. Clinically Relevant Volumes
    • 7. Role as Regulatory Cells
    • 8. Delivery of Gene Products
    • 9. Favorable Immune Status
    • 10. Commercially Available Research Tools

VII. Cord Blood Industry Accreditations

  • A. Overview of Cord Blood Industry Accreditation
  • B. AABB Accreditation

VIII. Key Processing Technologies within the Cord Blood Marketplace

  • A. AutoXpress® Platform ("AXP®") and BioArchive System (By Thermogenesis, a Division of Cesca Therapeutics)
  • B. Sepax (By Biosafe, in Eysins, Switzerland)
  • C. PrepaCyte®-CB (By BioE; Cryo-Cell Purchased Rights in U.S.)
  • D. Cord Blood 2.0TM (By Americord)
  • E. Other Cord Blood Processing Technologies

IX. Strategic Collaborations: Key Alliances within the Cord Blood Industry

  • A. Cord Blood Registry and Women's Health Alliance (Largest Women's Healthcare Groups)
  • B. ViaCord and Destination Maternity (Largest Retailer of Maternity Clothing)
  • C. Precious Cells Miracle and the Croydon Health Services NHS Trust
  • D. CarePilot and "Cord for Life" (Lifeforce Cryobank's Cord Blood Storage Program)
  • E. Cesca Therapeutics and UpState Public Cord Blood Bank
  • F. New York Blood Center and Pluristem Therapeutics Collaborate on Adjuvant Therapy for Cord Blood Transplantation

X. Pairing Cord Blood Banking with Prenatal / Neonatal / Maternal Health Services

  • A. Natera, a leader in genetic testing, launches EverCord™ Cord Blood and Tissue Banking Services (March 2017)
  • B. ViaCord, owned by PerkinElmer, Launched Newborn Genetic Screening (August 2017)
  • C. Human Longevity Inc. Acquired LifeBankUSA (owned by Celgene); LifeBankUSA Passed to Celularity, Inc.
  • D. AMAG Pharmaceuticals acquired Cord Blood Registry to Bolster Maternal Health Products (June 2015)
  • E. Donor Egg Bank Offers Free Processing of Client's Newborn Cord Blood through FamilyCord

XI. Cord Blood Industry Consolidation (Mergers and Acquisitions)

  • A. Global Analysis of Mergers & Acquisitions
  • B. Role of Holding Companies within the Global Cord Blood Industry

XII. Technologies for Cord Blood Stem Cell Expansion

  • A. Key Strategies for Cord Blood Expansion
    • 1. NiCord
    • 2. Notch-1 Ligand
    • 3. StemRegenin-1 (SR1)
    • 4. UM171
    • 5. Enforced Fucosylation
    • 6. Dimethyl Prostaglandin E2 (PGE2)
  • B. Case Study: Gamida Cell Ltd, Industry Leader in Cord Blood Expansion Technology

XIII. Diversification of Stem Cell Storage Services

  • A. Dental Stem Cell Storage
    • 1. Overview of Dental Stem Cell Storage
    • 2. Leading Dental Stem Cell Companies
    • 3. Timeline of Events for Dental Stem Cell Companies
    • 4. Key Competitors for Dental Stem Cell Storage
    • 5. BioEden, Leading Provider of Dental Stem Cell Storage Worldwide
  • B. Adipose-Derived Stem Cell Storage
  • C. Other Types of Stem Cell Storage

XIV. Comparison of U.S. Cord Blood Market Leaders

  • A. Cord Blood Registry
  • B. ViaCord
  • C. Cryo-Cell International
  • D. Comparison of Top 3 Private U.S. Cord Blood Banks

XV. Comparison of Global Cord Blood Market Leaders

  • A. Cryo-Save Group (an Esperite N.V Company)
  • B. China Cord Blood Corporation (Owned by Sanpower Group)
  • C. LifeCell International
  • D. Comparison of International Cord Blood Banks

XVI. SWOT Analysis for Cord Blood Industry

  • A. Strengths
  • B. Weaknesses
  • C. Opportunities
  • D. Threats

XVII. Regulation of the Cord Blood Marketplace

  • A. Regulation of HCT/Ps by the U.S. FDA
  • B. 21st Century Cures Act and REGROW Act
  • C. Accelerated Approval Pathways for Cell Therapies in Japan
  • D. Accelerated Approval Regulator Pathways Worldwide

XVIII. Trend Rate Analysis

  • A. Scientific Publication Rate Analysis
  • B. Grant Funding Analysis
  • C. Patent Analysis
  • D. Clinical Trial Analysis
  • E. Market Penetration Rate of Cord Blood Storage

XIX. Cord Blood Online Marketing Analysis

  • A. Cost to Win Online Traffic for the Term "Cord Blood" in Google AdWords
  • B. Cost to Win Online Traffic for the Term "Cord Tissue" in Google AdWords

XX. Key Cord Blood Industry Benchmarks

  • A. Medical Society Opinions of Cord Blood Banking
  • B. Rates of Parental Awareness
  • C. Rates of Worldwide Storage, by Year
  • D. Transplant Data
  • E. Impact of Haploidentical Transplant

XXI. Quality Guarantee Comparison

XXII. Market Size Analysis

  • A. Definitions
  • B. Methodology
    • 1. Roll-up All Competitor Sales ("Gold Standard")
    • 2. Weighted Analysis of Industry Leaders ("Silver Standard")
    • 3. Survey Customers for How Much They Spend in the Market ("Bronze Standard")
  • C. Types of Market Participants
    • 1. Largest Market Participants
    • 2. Mid-Sized Market Participants
    • 3. Small Sized Participants
    • 4. Public Cord Blood Banking Sector
    • 5. Summary of Findings
  • D. Market Size Determination for Cord Blood and Tissue Banking Market
  • E. Market Segmentation for All Applications of Cord Blood and Cord Tissue
    • 1. Biobanking
    • 2. Use in Hematopoietic Stem Cell Transplantation (HSCT)
    • 3. Cellular Therapies
    • 4. Genetic Manipulation
    • 5. Research Tools
  • F. Market Size Determinations by Market Segment

XXIII. Cord Blood Industry Leadership

  • B. Top Ten Most Influential Cord Blood Banks Worldwide
    • 1. Cord Blood Registry
    • 2. ViaCord
    • 3. Cryo-Cell International
    • 4. China Cord Blood Corporation (CCBC)
    • 5. Cryo-Save
    • 6. Cryoholdco
    • 7. LifeCell International
    • 8. Vita34 AG
    • 9. Crioestaminal
    • 10. National Cord Blood Program (NCBP) at the New York Blood Center

XXIV. Global Cord Blood Conferences and Events

XXV. Investors and Acquisitions Impacting the Global Cord Blood Industry

  • A. Investors Impacting the Global Cord Blood Market
  • B. Similarities between Acquisition of Cord Blood Registry & ViaCord

XXV. Geographic Analysis of Evolving Cord Blood Industry Conditions

  • A. China
  • B. France and Italy
  • C. Taiwan
  • D. Ecuador
  • E. South Africa
  • F. Brazil

XXVI. Summary of Conclusions

  • APPENDIX A -Conditions Treatable with Hematopoietic Stem Cell Transplant (Including Cord Blood Stem Cell Transplant)
  • APPENDIX B - AABB Accredited Cord Blood Banks Worldwide
  • APPENDIX C - List of U.S. Cord Blood Banks by Type of Bank (Private, Hybrid, or Public)
  • APPENDIX D - Global List of Cord Blood Banks Worldwide

List of Tables/Figures

  • FIGURE 1. Cord Blood Market Segmentation
  • FIGURE 2. Sources of Mesenchymal Stem Cells (MSCs)
  • FIGURE 3. Benefits of MSCs Relative to Other Stem Cells
  • FIGURE 4. Visualization of "Cord Blood" Clinical Trials (RePORTER Tool)
  • FIGURE 5. Leading Landing Page Used by CBR
  • FIGURE 6. Common Cryo-Cell Landing Page
  • FIGURE 7. Common ViaCord Landing Pages
  • FIGURE 8. Comparison of Umbilical Cord Blood vs. Umbilical Cord Tissue
  • FIGURE 9. Cord blood treatment options
  • FIGURE 10. Cost to Win Online Traffic for Term "Cord Blood" in Google AdWords on a Global Basis
  • FIGURE 11. Cost to Win Online Traffic for Term "Cord Blood" in Google AdWords within the U.S.
  • FIGURE 12. Density of Research Grants in the U.S. Containing "Cord Blood" in Description
  • FIGURE 13. Key Processing Technologies within the Cord Blood Banking Marketplace
  • FIGURE 14. Gamida Cell's Clinical Pipeline Involving Its Cord Blood Derived Products
  • FIGURE 15. Geographical Breakdown of "Cord Blood" Clinical Trials Registered at ClinicalTrials.gov
  • FIGURE 16. Ground-breaking Years in Transplant History
  • FIGURE 17. Key Dates in the Discovery of Mesenchymal Stem Cells
  • FIGURE 18. Map of Current Mesenchymal Stem Cell (MSC) Clinical Trials on ClinicalTrials.gov
  • FIGURE 19. Search Terms Containing the Phrase "Cord Blood" Within Them (Geography: USA Only)
  • FIGURE 20. Search Terms Containing the Phrase "Cord Blood" Within Them (Geography: Worldwide)
  • FIGURE 21. Sites of Organizations that Have Received Cord Blood Grants
  • FIGURE 22. Technical Advantages of Cord Blood over Bone Marrow or Peripheral Blood
  • FIGURE 23. Leading Assignees for Cord Blood Patents
  • FIGURE 24. Potential Strategies for Cord Blood Expansion
  • GRAPH 1. Likelihood of Requiring a Stem Cell Transplant (From Cord Blood, Bone Marrow, or Peripheral Blood)
  • GRAPH 2. # of "Cord Blood" Patents by Country (Title and Abstract Search)
  • GRAPH 3. # of Grants Funding Projects with "Cord Blood" in Description (RePORTER Tool)
  • GRAPH 4. Breakdown of Global Cord Blood and Tissue Market by Type of Participant
  • GRAPH 5. Countries with AABB Accredited Cord Blood Facilities
  • GRAPH 6. Market Contributions by Type of Market Participants
  • GRAPH 7. Market Contributions by Type of Market Segment
  • GRAPH 8. Number of Clinical Trials with "Cord Blood" in the Description
  • GRAPH 9. Number of Cord Blood Units in the BMDW Cord Blood Registry, by Year
  • GRAPH 10. Percentage of Cord Blood Banks Worldwide Offering Cord Tissue Storage Services
  • GRAPH 11. Percentage of Global Market for Cord Blood and Cord Tissue Banking
  • GRAPH 12. Registry Transplants by Cell Source
  • GRAPH 13. Types of Transplants Used by the 70,000 Patients Requiring Hematopoietic Stem Cell Transplantation Each Year
  • GRAPH 14. Year-Over-Year Comparison of Stem Cell Scientific Publications, by Stem Cell Type
  • TABLE 1. U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013 (Historical Snapshot 1)
  • TABLE 2. U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015 (Historical Snapshot 2)
  • TABLE 3. Adulthood Probability of Requiring a Stem Cell Transplant
  • TABLE 4. Breakdown of Global Market by Type of Participant
  • TABLE 5. Childhood Probability of Requiring a Stem Cell Transplant
  • TABLE 6. Clinical Trials Investigating the Use of Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
  • TABLE 7. Clinical Trials Underway Involving Use of Wharton's Jelly, a Rich Source of Cord Tissue MSCs
  • TABLE 8. Companies Offering Adipose-Derived Stem Cell Storage (Both Cord Blood Banks and Specialty Companies)
  • TABLE 9. Companies Offering Dental Stem Cell Storage, Including Cord Blood Banks and Specialty Companies
  • TABLE 20. Comparative Analysis of Pricing Among Leading U.S. Private Cord Blood Banks
  • TABLE 21. Comparison of Acquisition of Cord Blood Registry by AMAG Pharmaceuticals and ViaCord by PerkinElmer
  • TABLE 22. Comparison of Quality Guarantees Among Private U.S. Cord Blood Banks (Ranked by Value of the Guarantee)
  • TABLE 23. Comparison of Services and Features Among Leading Private Cord Blood Banks Worldwide
  • TABLE 24. Comparison of Services and Features Among Leading U.S. Private Cord Blood Banks
  • TABLE 25. Comparison of Stem Cell Publication Rates by Stem Cell Type
  • TABLE 26. Cord Blood Banking Opinions Issued by Medical Societies
  • TABLE 27. Cord Blood Clinical Trials Registered at ClinicalTrials.gov
  • TABLE 28. Cord Blood Units in the Bone Marrow Donors Worldwide Database
  • TABLE 29. Countries Containing AABB Accredited Cord Blood Banks
  • TABLE 30. Disease Categories That May Be Treatable with HSCT in the Future
  • TABLE 31. Disease Categories Treatable with Hematopoietic Stem Cell Transplantation (HSCT)
  • TABLE 32. Esperite N.V. Subsidiaries Operating Worldwide
  • TABLE 33. Free Cord Blood Programs for Families in Need in the U.S.
  • TABLE 34. Geographic Breakdown of "Cord Blood" Clinical Trials Registered at ClinicalTrials.gov
  • TABLE 35. Global Cord Blood Conference and Events
  • TABLE 36. Global Private Cord Blood and Tissue Banking Market, by Type of Market Participant
  • TABLE 37. Google AdWords Pay-Per-Click Prices for Cord Blood Related Search Terms
  • TABLE 38. Industry Investors within the Cord Blood Market
  • TABLE 39. Major Acquisitions within the Global Cord Blood Market
  • TABLE 40. Market Contribution in USD ($) by Market Segment
  • TABLE 41. Market Contribution in USD ($) by Type of Market Participant
  • TABLE 42. Market Size Determinations by Market Segment
  • TALBE 43. Number of Cord Blood and Tissue Units Stored by Mid-Sized Private Cord Blood Banks
  • TABLE 44. Number of Cord Blood and Tissue Units Stored in Largest Private Cord Blood Banks
  • TABLE 45. Opportunities within the Global Cord Blood Banking Market
  • TABLE 46. Patents Containing "Cord Blood" in the Title or Abstract (Google Patent Search)
  • TABLE 47. Percent of Cord Blood Banks Worldwide Offering Cord Tissue Storage Services
  • TABLE 48. Percent of Total Global Market by Type of Cord Blood Bank
  • TABLE 49. Pricing Structures for Umbilical Cord Tissue
  • TABLE 50. Strengths of the Global Cord Blood Banking Market
  • TABLE 51. Threats to the Global Cord Blood Banking Market
  • TABLE 52. Timeline of Key Events within the Cord Blood Industry
  • Table 53. Transplants by Cell Source
  • TABLE 54. Trend Rate Analysis of Cord Blood and Cord Tissue Scientific Publications
  • TABLE 55. Trend Rate Analysis of Cord Blood Grants (RePORTER Tool)
  • TABLE 56. Trends in Cord Blood Industry Growth by Geography and Sector
  • TABLE 57. Types of Stem Cell Banking
  • TABLE 58. Unique Differentiators for CBR, ViaCord, and Cryo-Cell
  • TABLE 59. Weaknesses of the Global Cord Blood Banking Market
  • TABLE 60: Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation
  • TABLE 61: Adult Sources for Mesenchymal Stem Cell (MSC) Isolation
  • TABLE 62: Cord Blood Banks Securing Cord Blood Patents as the Assignee
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research